The prolactinoma

Best Practice and Research: Clinical Endocrinology and Metabolism

Volumn 23, Issue 5, 2009, Pages 575-596

  Colao, Annamaria ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

bromocriptine; cabergoline; dopamine agonists; medical therapy; prolactinomas; quinagolide; radiotherapy; surgery

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; LISURIDE; METERGOLINE; PERGOLIDE; PROLACTIN; QUINAGOLIDE; SOMATOSTATIN DERIVATIVE; TEMOZOLOMIDE; TERGURIDE; ANTINEOPLASTIC AGENT;

AUDITORY HALLUCINATION; CANCER INHIBITION; CANCER RADIOTHERAPY; CLINICAL FEATURE; CLINICAL TRIAL; CRANIOTOMY; DELUSION; DIZZINESS; DROWSINESS; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG HALF LIFE; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG RESPONSE; DRUG WITHDRAWAL; ENDOCRINE SURGERY; HEART VALVE REGURGITATION; HUMAN; HYPERPROLACTINEMIA; MOLECULAR MECHANICS; MOOD DISORDER; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; ORTHOSTATIC HYPOTENSION; OUTCOME ASSESSMENT; PREGNANCY; PREVALENCE; PROLACTIN BLOOD LEVEL; PROLACTINOMA; PSYCHOSIS; REMISSION; REVIEW; SYNCOPE; TREATMENT INDICATION; TREATMENT RESPONSE; VASOSPASM; VOMITING; DRUG RESISTANCE; FEMALE; HYPOPHYSIS TUMOR; PHYSIOLOGY; PREGNANCY COMPLICATION; TREATMENT OUTCOME; TREATMENT WITHDRAWAL;

ANTINEOPLASTIC AGENTS; DOPAMINE AGONISTS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; PITUITARY NEOPLASMS; PREGNANCY; PREGNANCY COMPLICATIONS, NEOPLASTIC; PROLACTINOMA; TREATMENT OUTCOME; WITHHOLDING TREATMENT;

EID: 71749116644     PISSN: 1521690X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beem.2009.05.003     Document Type: Review

References (157)

1. Gillam M.P., Molitch M.E., Lombardi G., et al. Advances in the treatment of prolactinomas. Endocrine Reviews 27 (2006) 485-534
2. Schlechte J.A. Clinical practice. Prolactinoma. The New England Journal of Medicine 349 (2003) 2035-2041
3. Colao A., and Lombardi G. Growth hormone and prolactin excess. Lancet 352 (1998) 1455-1461
4. Cunnah D., and Besser M. Management of prolactinomas. Clinical Endocrinology 34 (1991) 231-235
5. Daly A.F., Rixhon M., Adam C., et al. High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. The Journal of Clinical Endocrinology Metabolism 91 (2006) 4769-4775
6. Colao A., Sarno A.D., Cappabianca P., et al. Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia. European Journal of Endocrinology 148 (2003) 325-331
7. Mindermann T., and Wilson C.B. Age-related and gender-related occurrence of pituitary adenomas. Clinical Endocrinology 41 (1994) 359-364
8. Colao A. Pituitary tumors in childhood. In: New MI [ed] Endotext.org, 2004.
9. Burgess J.R., Shepard J.J., Parameswaran V., et al. Prolactinomas in a large kindred with multiple endocrine neoplasia type 1: clinical features and inheritance pattern. The Journal of Clinical Endocrinology Metabolism 81 (1996) 1841-1845
10. Vergès B., Boureille F., Goudet P., et al. Pituitary disease in MEN type 1 [MEN1]: data from the France-Belgium MEN1 multicenter study. The Journal of Clinical Endocrinology Metabolism 87 (2002) 457-465
11. Burrow G.N., Wortzman G., Rewcastle N.B., et al. Microadenomas of the pituitary gland and abnormal sellar tomograms in an unselected autopsy series. The New England Journal of Medicine 304 (1980) 156-158
12. Delgrange E., Trouillas J., Maiter D., et al. Sex-related difference in the growth of prolactinomas: a clinical and proliferation marker study. The Journal of Clinical Endocrinology Metabolism 82 (1997) 2102-2107
13. Berezin M., Shimon I., and Hadani M. Prolactinoma in 53 men: clinical characteristics and modes of treatment (male prolactinoma). Journal of Endocrinological Investigation 18 (1995) 436-441
14. Walsh J.P., and Pullan P.T. Hyperprolactinaemia in males: a heterogeneous disorder. Australian and New Zealand Journal of Medicine 27 (1997) 385-390
15. Pinzone J.J., Katznelson L., Danila D.C., et al. Primary medical therapy of micro- and macroprolactinomas in men. The Journal of Clinical Endocrinology Metabolism 85 (2000) 3053-3057
16. De Rosa M., Zarrilli S., Di Sarno A., et al. Hyperprolactinemia in men. Clinical and biochemical features and response to treatment. Endocrine 20 1-2 (2003) 75-82
17. Johri A.M., Heaton J.P., and Morales A. Severe erectile dysfunction is a marker for hyperprolactinemia. International Journal of Impotence Research 13 (2001) 176-182
18. Rehman J., Christ G., Alyskewycz M., et al. Experimental hyperprolactinemia in a rat model: alteration in centrally mediated neuroerectile mechanism. International Journal of Impotence Research 12 (2000) 23-32
19. De Rosa M., Zarrilli S., Vitale G., et al. Six months of treatment with cabergoline restores sexual potency in hyperprolactinemic males: an open longitudinal study monitoring nocturnal penile tumescence. The Journal of Clinical Endocrinology Metabolism 89 2 (2004) 621-625
20. Naliato E.C., Violante A.H., Caldas D., et al. Body fat in nonobese women with prolactinoma treated with dopamine agonists. Clinical Endocrinology 67 (2007) 845-852
21. Greenspan S.L., Oppenheim D.S., and Klibanski A. Importance of gonadal steroids to bone mass in men with hyperprolactinemic hypogonadism. Annals of Internal Medicine 110 (1989) 526-531
22. Kayath M.J., Lengyel A.M., and Vieira J.G. Prevalence and magnitude of osteopenia in patients with prolactinoma. Brazilian Journal of Medical and Biological Research 26 (1993) 933-941
23. Colao A., Di Somma C., Loche S., et al. Prolactinomas in adolescents: persistent bone loss after 2 years of prolactin normalization. Clinical Endocrinology 52 (2000) 319-327
24. Kars M., van der Klaauw A.A., Onstein C.S., et al. Quality of life is decreased in female patients treated for microprolactinoma. European Journal of Endocrinology 157 (2007) 133-139
25. Cesar de Oliveira Naliato E., Dutra Violante A.H., Caldas D., et al. Quality of life in women with microprolactinoma treated with dopamine agonists. Pituitary 11 (2008) 247-254
26. Di Sarno A., Rota F., Auriemma R., et al. An evaluation of patients with hyperprolactinemia: have dynamic tests had their day?. Journal of Endocrinological Investigation 26 7 Suppl. (2003) 39-47
27. Cavaco B., Leite V., Santos M.A., et al. Some forms of big big prolactin behave as a complex of monomeric with an immunoglobulin G in patients with macroprolactinoma or prolactinomas. The Journal of Clinical Endocrinology Metabolism 80 (1995) 3507-3512
28. Hattori N., Ikekubo K., Ishihara T., et al. Effects of antiprolactin autoantibodies on serum prolactin measurements. European Journal of Endocrinology 130 (1994) 434-437
29. Petakov M.S., Damjanovic' S.S., Nikolic'-Durovic' M.M., et al. Pituitary adenomas secreting large amounts of prolactin may give false low values in immunoradiometric assays. The hook effect. Journal of Endocrinological Investigation 21 (1998) 184-188
30. Biller B.M. Diagnostic evaluation of hyperprolactinemia. The Journal of Reproductive Medicine 44 12 Suppl. (1999) 1095-1099
31. Koppelman M.C., Jaffe M.J., Rieth K.G., et al. Hyperprolactinemia, amenorrhea, and galactorrhea. A retrospective assessment of twenty-five cases. Annals of Internal Medicine 100 (1984) 115-121
32. March C.M., Kletzky O.A., Davajan V., et al. Longitudinal evaluation of patients with untreated prolactin-secreting pituitary adenomas. American Journal of Obstetrics and Gynecology 139 (1981) 835-844
33. Schlechte J., Dolan K., Sherman B., et al. The natural history of untreated hyperprolactinemia: a prospective analysis. The Journal of Clinical Endocrinology Metabolism 68 (1989) 412-418
34. Sisam D.A., Sheehan J.P., and Sheeler L.R. The natural history of untreated microprolactinomas. Fertility and Sterility 48 (1987) 67-71
35. Von Werder K., Eversmann T., Fahlbusch R., et al. Development of hyperprolactinemia in patients with adenomas with and without prior operative treatment. Excerpta Medica International Congress series 584 (1982) 175-188
36. Weiss M.H., Teal J., Gott P., et al. Natural history of microprolactinomas: six-year follow-up. Neurosurgery 12 (1983) 180-183
37. Hofle G., Gasser R., Mohsenipour I., et al. Surgery combined with dopamine agonists versus dopamine agonists alone in long-term treatment of macroprolactinoma: a retrospective study. Experimental and Clinical Endocrinology & Diabetes 106 (1998) 211-216
38. Watt A., Pobereskin L., and Vaidya B. Pituitary apoplexy within a macroprolactinoma. Nature Clinical Practice Endocrinology & Metabolism 4 (2008) 635-641
39. Jho H.D. Endoscopic pituitary surgery. Pituitary 2 (1999) 139-154
40. Cappabianca P., Cavallo L.M., and de Divitiis E. Endoscopic endonasal transsphenoidal surgery. Neurosurgery 55 (2004) 933-940 discussion 940-1
41. Cappabianca P., Cavallo L.M., Colao A., et al. Surgical complications associated with the endoscopic endonasal transsphenoidal approach for pituitary adenomas. Journal of Neurosurgery 97 (2002) 293-298
42. Zada G., Kelly D.F., Cohan P., et al. Endonasal transsphenoidal approach for pituitary adenomas and other sellar lesions: an assessment of efficacy, safety, and patient impressions. Journal of Neurosurgery 98 (2003) 350-358
43. Cho D.Y., and Liau W.R. Comparison of endonasal endoscopic surgery and sublabial microsurgery for prolactinomas. Surgical Neurology 58 (2002) 371-375 discussion 375-6
44. Kawamata T., Iseki H., Ishizaki R., et al. Minimally invasive endoscope-assisted endonasal trans-sphenoidal microsurgery for pituitary tumors: experience with 215 cases comparing with sublabial trans-sphenoidal approach. Neurological Research 24 (2002) 259-265
45. Charpentier G., de Plunkett T., Jedynak P., et al. Surgical treatment of prolactinomas. Short- and long-term results, prognostic factors. Hormone Research 22 (1985) 222-227
46. Fahlbusch R., and Buchfelder M. Present status of neurosurgery in the treatment of prolactinomas. Neurosurgical Review 8 (1985) 195-205
47. Landolt A.M. Surgical treatment of pituitary prolactinomas: postoperative prolactin and fertility in seventy patients. Fertility and Sterility 35 (1981) 620-625
48. Rawe S.E., Williamson H.O., Levine J.H., et al. Prolactinomas: surgical therapy, indications and results. Surgical Neurology 14 (1980) 161-167
49. Scanlon M.F., Peters J.R., Thomas J.P., et al. Management of selected patients with hyperprolactinaemia by partial hypophysectomy. British Medical Journal (Clinical Research Ed) 291 (1985) 1547-1550
50. Serri O., Rasio E., Beauregard H., et al. Recurrence of hyperprolactinemia after selective transsphenoidal adenomectomy in women with prolactinoma. The New England Journal of Medicine 309 (1983) 280-283
51. Nicola G.C., Tonnarelli G.P., and Griner A. One hundredand ten prolactin secreting adenomas: results of surgical treatment. In: Faglia G., Giovanelli M., and MacLeod R.M. (Eds). Pituitary microadenomas (1980), Academic Press, New York 483-486
52. Faria Jr. M.A., and Tindall G.T. Transsphenoidal microsurgery for prolactin-secreting pituitary adenomas. Journal of Neurosurgery 56 (1982) 33-43
53. Randall R.V., Laws Jr. E.R., Abboud C.F., et al. Transsphenoidal microsurgical treatment of prolactin-producing pituitary adenomas. Results in 100 patients. Mayo Clinic Proceedings Mayo Clinic 58 (1983) 108-121
54. Hardy J. Transsphenoidal microsurgery of prolactinomas. In: Black P.M., Zervas N.T., and Ridgway E.C. (Eds). Secretory tumors of the pituitary gland (1984), Raven Press, New York 73-81
55. Arafah B.M., Brodkey J.S., and Pearson O.H. Gradual recovery of lactotroph responsiveness to dynamic stimulation following surgical removal of prolactinomas: long-term follow-up studies. Metabolism 35 (1986) 905-912
56. Guidetti B., Fraioli B., and Cantore G.P. Results of surgical management of 319 pituitary adenomas. Acta Neurochirurgica 85 (1987) 117-124
57. Giovanelli M., Losa M., Mortini P., et al. Surgical results in microadenomas. Acta Neurochirurgica 65 Suppl. (1996) 11-12
58. Tyrrell J.B., Lamborn K.R., Hannegan L.T., et al. Transsphenoidal microsurgical therapy of prolactinomas: initial outcomes and long-term results. Neurosurgery 44 (1999) 254-261 discussion 261-3
59. Gokalp H.Z., Deda H., Attar A., et al. The neurosurgical management of prolactinomas. Journal of Neurosurgical Sciences 44 (2000) 128-132
60. Amar A.P., Couldwell W.T., Chen J.C., et al. Predictive value of serum prolactin levels measured immediately after transsphenoidal surgery. Journal of Neurosurgery 97 (2002) 307-314
61. Mortini P., Losa M., Barzaghi R., et al. Results of transsphenoidal surgery in a large series of patients with pituitary adenoma. Neurosurgery 56 (2005) 1222-1233 discussion 1233
62. Ciccarelli E., Ghigo E., Miola C., et al. Long-term follow-up of 'cured' prolactinoma patients after successful adenomectomy. Clinical Endocrinology 32 (1990) 583-592
63. Massoud F., Serri O., Hardy J., et al. Transsphenoidal adenomectomy for microprolactinomas: 10 to 20 years of follow-up. Surgical Neurology 45 (1996) 341-346
64. Thomson J.A., Gray C.E., and Teasdale G.M. Relapse of hyperprolactinemia after transsphenoidal surgery for microprolactinoma: lessons from long-term follow-up. Neurosurgery 50 (2002) 36-39 discussion 39-40
65. Pan L., Zhang N., Wang E.M., et al. Gamma knife radiosurgery as a primary treatment for prolactinomas. Journal of Neurosurgery 93 Suppl. 3 (2000) 10-13
66. Landolt A.M., and Lomax N. Gamma knife radiosurgery for prolactinomas. Journal of Neurosurgery 93 Suppl. 3 (2000) 14-18
67. Rocher F.P., Sentenac I., Berger C., et al. Stereotactic radiosurgery: the Lyon experience. Acta Neurochirurgica 63 Suppl. (1995) 109-114
68. Leber K.A., Bergloff J., and Pendl G. Dose-response tolerance of the visual pathways and cranial nerves of the cavernous sinus to stereotactic radiosurgery. Journal of Neurosurgery 88 (1998) 43-50
69. Tishler R.B., Loeffler J.S., Lunsford L.D., et al. Tolerance of cranial nerves of the cavernous sinus to radiosurgery. International Journal of Radiation Oncology, Biology, Physics 27 (1993) 215-221
70. Brada M., Ajithkumar T.V., and Minniti G. Radiosurgery for pituitary adenomas. Clinical Endocrinology 61 (2004) 531-534
71. Chen J.C., Giannotta S.L., Yu C., et al. Radiosurgical management of benign cavernous sinus tumors: dose profiles and acute complications. Neurosurgery 48 (2001) 1022-1030 discussion 1030-2
72. Snyder P.J., Fowble B.F., Schatz N.J., et al. Hypopituitarism following radiation therapy of pituitary adenomas. The American Journal of Medicine 81 (1986) 457-462
73. Littley M.D., Shalet S.M., Beardwell C.G., et al. Hypopituitarism following external radiotherapy for pituitary tumours in adults. The Quarterly Journal of Medicine 70 (1989) 145-160
74. Tomlinson J.W., Holden N., Hills R.K., et al. Association between premature mortality and hypopituitarism. West Midlands Prospective Hypopituitary Study Group. Lancet 357 (2001) 425-431
75. Erfurth E.M., Bulow B., Mikoczy Z., et al. Is there an increase in second brain tumours after surgery and irradiation for a pituitary tumour?. Clinical Endocrinology 55 (2001) 613-616
76. Minniti G., Traish D., Ashley S., et al. Risk of second brain tumor after conservative surgery and radiotherapy for pituitary adenoma: update after an additional 10 years. The Journal of Clinical Endocrinology Metabolism 90 (2005) 800-804
77. Hoybye C., Grenback E., Rahn T., et al. Adrenocorticotropic hormone-producing pituitary tumors: 12- to 22-year follow-up after treatment with stereotactic radiosurgery. Neurosurgery 49 (2001) 284-291 discussion 291-2
78. Witt T.C. Stereotactic radiosurgery for pituitary tumors. Neurosurg Focus 14 (2003) e10
79. Sheehan J.P., Niranjan A., Sheehan J.M., et al. Stereotactic radiosurgery for pituitary adenomas: an intermediate review of its safety, efficacy, and role in the neurosurgical treatment armamentarium. Journal of Neurosurgery 102 (2005) 678-691
80. Colao A., Annunziato L., and Lombardi G. Treatment of prolactinomas. Annals of Internal Medicine 30 (1998) 452-459
81. Colao A., Di Sarno A., Pivonello R., et al. Dopamine receptor agonists for treating prolactinomas. Expert Opinion on Investigational Drugs 11 (2002) 787-800
82. Klibanski A., and Greenspan S.L. Increase in bone mass after treatment of hyperprolactinemic amenorrhea. The New England Journal of Medicine 315 (1986) 542-546
83. Di Somma C., Colao A., Di Sarno A., et al. Bone marker and bone density responses to dopamine agonist therapy in hyperprolactinemic males. The Journal of Clinical Endocrinology Metabolism 83 (1998) 807-813
84. De Rosa M., Colao A., Di Sarno A., et al. Cabergoline treatment rapidly improves gonadal function in hyperprolactinemic males: a comparison with bromocriptine. European Journal of Endocrinology 138 (1998) 286-293
85. Di Sarno A., Landi M.L., Cappabianca P., et al. Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy. The Journal of Clinical Endocrinology Metabolism 86 (2001) 5256-5261
86. Colao A., Pivonello R., Di Somma C., et al. Medical therapy of pituitary adenomas: effects on tumor shrinkage. Reviews in Endocrine & Metabolic Disorders (2008 Sep 13) [Epub ahead of print]
87. Colao A., Di Sarno A., Landi M.L., et al. Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients. The Journal of Clinical Endocrinology Metabolism 85 (2000) 2247-2252
88. Lamberts S.W., and Quik R.F. A comparison of the efficacy and safety of pergolide and bromocriptine in the treatment of hyperprolactinemia. The Journal of Clinical Endocrinology Metabolism 72 (1991) 635-641
89. Colao A., De Rosa M., Sarnacchiaro F., et al. Chronic treatment with CV 205-502 restores the gonadal function in hyperprolactinemic males. European Journal of Endocrinology 135 (1996) 548-552
90. Liuzzi A., Dallabonzana D., Oppizzi G., et al. Low doses of dopamine agonists in the long-term treatment of macroprolactinomas. The New England Journal of Medicine 313 (1985) 656-659
91. Dallabonzana D., Liuzzi A., Oppizzi G., et al. Chronic treatment of pathological hyperprolactinemia and acromegaly with the new ergot derivative terguride. The Journal of Clinical Endocrinology Metabolism 63 (1986) 1002-1007
92. Turner T.H., Cookson J.C., Wass J.A., et al. Psychotic reactions during treatment of pituitary tumours with dopamine agonists. British Medical Journal (Clinical Research Ed) 289 (1984) 1101-1103
93. Zanettini R., Antonini A., Gatto G., et al. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. The New England Journal of Medicine 356 (2007) 39-46
94. Schade R., Andersohn F., Suissa S., et al. Dopamine agonists and the risk of cardiac-valve regurgitation. The New England Journal of Medicine 356 (2007) 29-38
95. Lancellotti P., Livadariu E., Markov M., et al. Cabergoline and the risk of valvular lesions in endocrine disease. European Journal of Endocrinology 159 (2008) 1-5
96. Vallette S., Serri K., Rivera J., et al. Long-term cabergoline therapy is not associated with valvular heart disease in patients with prolactinomas. Pituitary (2008 Jul 2) [Epub ahead of print]
97. Kars M., Delgado V., Holman E.R., et al. Aortic valve calcification and mild tricuspid regurgitation but no clinical heart disease after 8 years of dopamine agonist therapy for prolactinoma. The Journal of Clinical Endocrinology Metabolism 93 (2008) 3348-3356
98. Devin J.K., Lakhani V.T., Byrd III B.F., et al. Prevalence of valvular heart disease in a cohort of patients taking cabergoline for management of hyperprolactinemia. Endocrine Practice 14 (2008) 672-677
99. Colao A., Galderisi M., Di Sarno A., et al. Increased prevalence of tricuspid regurgitation in patients with prolactinomas chronically treated with cabergoline. The Journal of Clinical Endocrinology Metabolism 93 (2008) 3777-3784
100. Wakil A., Rigby A.S., Clark A.L., et al. Low dose cabergoline for hyperprolactinaemia is not associated with clinically significant valvular heart disease. European Journal of Endocrinology 159 (2008) R11-R14
101. Bogazzi F., Buralli S., Manetti L., et al. Treatment with low doses of cabergoline is not associated with increased prevalence of cardiac valve regurgitation in patients with hyperprolactinaemia. International Journal of Clinical Practice 62 (2008) 1864-1869
102. Herring N., Szmigielski C., Becher H., et al. Valvular heart disease and the use of cabergoline for the treatment of prolactinoma. Clinical Endocrinology 70 (2009) 104-108
103. Ono M., Miki N., Kawamata T., et al. Prospective study of high-dose cabergoline treatment of prolactinomas in 150 patients. The Journal of Clinical Endocrinology Metabolism 93 (2008) 4721-4727
104. Nachtigall LB, Valassi E, McCaty D, et al. Cardiac valvular function in hyperprolactinemic patients receiving cabergoline. Program of the 90th Annual Meeting of The Endocrine Society, San Francisco, CA, 2008, p 124 [Abstract OR27-2].
105. Kars M., Pereira A.M., Bax J.J., et al. Cabergoline and cardiac valve disease in prolactinoma patients: additional studies during long-term treatment are required. European Journal of Endocrinology 159 (2008) 363-367
106. Johnston D.G., Prescott R.W., Kendall-Taylor P., et al. Hyperprolactinemia. Long-term effects of bromocriptine. Annals of Internal Medicine 75 (1983) 868-874
107. Colao A., Di Sarno A., Cappabianca P., et al. Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia. The New England Journal of Medicine 349 (2003) 2023-2033
108. Zarate A., Canales E.S., Cano C., et al. Follow-up of patients with prolactinomas after discontinuation of long-term therapy with bromocriptine. Acta Endocrinologica 104 (1983) 139-142
109. Johnston D.G., Hall K., Kendall-Taylor P., et al. Effect of dopamine agonist withdrawal after long-term therapy in prolactinomas. Studies with high-definition computerised tomography. Lancet 2 (1984) 187-192
110. Maxson W.S., Dudzinski M., Handwerger S.H., et al. Hyperprolactinemic response after bromocriptine withdrawal in women with prolactin-secreting pituitary tumors. Fertility and Sterility 41 (1984) 218-223
111. Moriondo P., Travaglini P., Nissim M., et al. Bromocriptine treatment of microprolactinomas: evidence of stable prolactin decrease after drug withdrawal. The Journal of Clinical Endocrinology Metabolism 60 (1985) 764-772
112. Winkelmann W., Allolio B., Deuss U., et al. Persisting normoprolactinemia after withdrawal of bromocriptine long-term therapy in patients with prolactinomas. In: MacLeod R.M., Thorner M.O., and Scapagnini U. (Eds). Basic and clinical correlates (1985), Liviana Press, Padova 817-822
113. Wang C., Lam K.S., Ma J.T., et al. Long-term treatment of hyperprolactinaemia with bromocriptine: effect of drug withdrawal. Clinical Endocrinology 27 (1987) 363-371
114. Rasmussen C., Brownell J., and Bergh T. Clinical response and prolactin concentration in hyperprolactinemic women during and after treatment for 24 months with the new dopamine agonist, CV 205-502. Acta Endocrinologica 125 (1991) 170-176
115. van't Verlaat J.W., and Croughs R.J. Withdrawal of bromocriptine after long-term therapy for macroprolactinomas; effect on plasma prolactin and tumour size. Clinical Endocrinology 34 (1991) 175-178
116. Passos V.Q., Souza J.J., Musolino N.R., et al. Long-term follow-up of prolactinomas: normoprolactinemia after bromocriptine withdrawal. The Journal of Clinical Endocrinology Metabolism 87 (2002) 3578-3582
117. Biswas M., Smith J., Jadon D., et al. Long-term remission following withdrawal of dopamine agonist therapy in subjects with microprolactinomas. Clinical Endocrinology 63 (2005) 26-31
118. Di Sarno A., Landi M.L., Marzullo P., et al. The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas. Clinical Endocrinology 53 (2000) 53-60
119. Ferrari C., Paracchi A., Mattei A.M., et al. Cabergoline in the long-term therapy of hyperprolactinemic disorders. Acta Endocrinologica 126 (1992) 489-494
120. Muratori M., Arosio M., Gambino G., et al. Use of cabergoline in the long-term treatment of hyperprolactinemic and acromegalic patients. Journal of Endocrinological Investigation 20 (1997) 537-546
121. Cannavò S., Curto L., Squadrito S., et al. Cabergoline: a first-choice treatment in patients with previously untreated prolactin-secreting pituitary adenoma. Journal of Endocrinological Investigation 22 (1999) 354-359
122. Colao A., Di Sarno A., Guerra E., et al. Predictors of remission of hyperprolactinaemia after long-term withdrawal of cabergoline therapy. Clinical Endocrinology 67 (2007) 426-433
123. Crosignani P.G., Mattei A.M., Severini V., et al. Long-term effects of time, medical treatment and pregnancy in 176 hyperprolactinemic women. European Journal of Obstetrics, Gynecology, and Reproductive Biology 44 (1992) 175-180
124. Jeffcoate W.J., Pound N., Sturrock N.D., et al. Long-term follow-up of patients with hyperprolactinaemia. Clinical Endocrinology 45 (1996) 299-303
125. Karunakaran S., Page R.C., and Wass J.A. The effect of the menopause on prolactin levels in patients with hyperprolactinaemia. Clinical Endocrinology 54 (2001) 295-300
126. Molitch M.E. The cabergoline-resistant prolactinoma patient: new challenges. The Journal of Clinical Endocrinology Metabolism 93 (2008) 4643-4645
127. Bression D., Brandi A.M., Martres M.P., et al. Dopaminergic receptors in human prolactin-secreting adenomas: a quantitative study. The Journal of Clinical Endocrinology Metabolism 51 (1980) 1037-1044
128. Pellegrini I., Rasolonjanahary R., Gunz, et al. Resistance to bromocriptine in prolactinomas. The Journal of Clinical Endocrinology Metabolism 69 (1989) 500-509
129. Caccavelli L., Feron F., Morange I., et al. Decreased expression of the two D2 dopamine receptor isoforms in bromocriptine-resistant prolactinomas. Neuroendocrinology 60 (1994) 314-322
130. Friedman E., Adams E.F., Hoog A., et al. Normal structural dopamine type 2 receptor gene in prolactin-secreting and other pituitary tumors. The Journal of Clinical Endocrinology Metabolism 78 (1994) 568-574
131. Filopanti M., Barbieri A.M., Angioni A.R., et al. Dopamine D2 receptor gene polymorphisms and response to cabergoline therapy in patients with prolactin-secreting pituitary adenomas. The Pharmacogenomics Journal 8 (2008) 357-363
132. Dallabonzana D., Spelta B., Oppizzi G., et al. Reenlargement of macroprolactinomas during bromocriptine treatment: report of two cases. Journal of Endocrinological Investigation 6 (1983) 47-50
133. Breidahl H.D., Topliss D.J., and Pike J.W. Failure of bromocriptine to maintain reduction in size of a macroprolactinoma. British Medical Journal (Clinical Research Ed) 287 (1983) 451-452
134. Winkelmann J., Pagotto U., Theodoropoulou M., et al. Retention of dopamine 2 receptor mRNA and absence of the protein in craniospinal and extracranial metastasis of a malignant prolactinoma: a case report. European Journal of Endocrinology 146 (2002) 81-88
135. Delgrange E., Crabbe J., and Donckier J. Late development of resistance to bromocriptine in a patient with macroprolactinoma. Hormone Research 49 (1998) 250-253
136. Verhelst J., Abs R., Maiter D., et al. Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. The Journal of Clinical Endocrinology Metabolism 84 (1999) 2518-2522
137. Colao A., Di Sarno A., Sarnacchiaro F., et al. Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment. The Journal of Clinical Endocrinology Metabolism 82 (1997) 876-883
138. Brue T., Pellegrini I., Gunz G., et al. Effects of the dopamine agonist CV 205-502 in human prolactinomas resistant to bromocriptine. The Journal of Clinical Endocrinology Metabolism 74 (1992) 577-584
139. Glaser B., Nesher Y., and Barziliai S. Long-term treatment of bromocriptine-intolerant prolactinoma patients with CV 205-502. The Journal of Reproductive Medicine 39 (1994) 449-454
140. Morange I., Barlier A., Pellegrini I., et al. Prolactinomas resistant to bromocriptine: long-term efficacy of quinagolide and outcome of pregnancy. European Journal of Endocrinology 135 (1996) 413-420
141. De Luis D.A., Becerra A., Lahera M., et al. A randomized cross-over study comparing cabergoline and quinagolide in the treatment of hyperprolactinemic patients. Journal of Endocrinological Investigation 23 (2000) 428-434
142. Webster J. Cabergoline and quinagolide therapy for prolactinomas. Clinical Endocrinology 53 (2000) 549-550
143. Ahmed S.R., and Shalet S.M. Discordant responses of prolactinoma to two different dopamine agonists. Clinical Endocrinology 24 (1986) 421-426
144. Berezin M., Avidan D., and Baron E. Long-term pergolide treatment of hyperprolactinemic patients previously unsuccessfully treated with dopaminergic drugs. Israel Journal of Medical Sciences 27 (1991) 375-379
145. Molitch M.E., Elton R.L., Blackwell R.E., et al. Bromocriptine as primary therapy for prolactin-secreting macroadenomas: results of a prospective multicenter study. The Journal of Clinical Endocrinology Metabolism 60 (1985) 698-705
146. Freda P.U., Andreadis C.I., Khandji A.G., et al. Long-term treatment of prolactin-secreting macroadenomas with pergolide. The Journal of Clinical Endocrinology Metabolism 85 (2000) 8-13
147. Colao A, Ochoa AS, Auriemma RS, et al. Pituitary carcinomas. Frontiers of Hormone Research, in press.
148. Radwanska E., McGarrigle H.H., Little V., et al. Induction of ovulation in women with hyperprolactinemic amenorrhea using clomiphene and human chorionic gonadotropin of bromocriptine. Fertility and Sterility 32 (1979) 187-192
149. Bergh T., Skarin G., Nillius S.J., et al. Pulsatile GnRH therapy-an alternative successful therapy for induction of ovulation in infertile normo- and hyperprolactinaemic amenorrhoeic women with pituitary tumours. Acta Endocrinologica 110 (1985) 440-444
150. Gindoff P.R., Loucopoulos A., and Jewelewicz R. Treatment of hyperprolactinemic amenorrhea with pulsatile gonadotropin-releasing hormone therapy. Fertility and Sterility 46 (1986) 1156-1158
151. McGarrigle H.H., Sarris S., Little V., et al. Induction of ovulation with clomiphene and human chorionic gonadotrophin in women with hyperprolactinaemic amenorrhoea. British Journal of Obstetrics and Gynaecology 85 (1978) 692-697
152. Recombinant human luteinizing hormone (LH) to support recombinant human follicle-stimulating hormone (FSH)-induced follicular development in LH- and FSH-deficient anovulatory women: a dose-finding study. The European Recombinant Human LH Study Group. The Journal of Clinical Endocrinology Metabolism 83 (1998) 1507-1514
153. Divers Jr. W.A., and Yen S.S. Prolactin-producing microadenomas in pregnancy. Obstetrics and Gynecology 62 (1983) 425-429
154. Colao A., Abs R., Bárcena D.G., et al. Pregnancy outcomes following cabergoline treatment: extended results from a 12-year observational study. Clinical Endocrinology 8 1 (2008) 66-71
155. Belchetz P.E., Carty A., Clearkin L.G., et al. Failure of prophylactic surgery to avert massive pituitary expansion in pregnancy. Clinical Endocrinology 25 (1986) 325-330
156. Ruiz-Velasco V., and Tolis G. Pregnancy in hyperprolactinemic women. Fertility and Sterility 41 (1984) 793-805
157. Molitch M.E. Pituitary disorders during pregnancy. Endocrinology and Metabolism Clinics of North America 35 1 (2006) 99-116